← All trials
NCT00989157
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2009
- Primary completion
- Oct 1, 2012
- Completion date
- Nov 1, 2012
- First posted
- —
- Last posted
- —
- Enrollment
- 20
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- Neuropsychiatric Research Institute, Fargo, NDLead sponsor
- University of North DakotaOverall official - principal investigator
- University of North DakotaCollaborator
- Eli LillyCollaborator
- Neuropsychiatric Research Institute, Fargo, NDReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.